Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphoma 1Breast Neoplasms 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × TER 286 × Clear all
NCT01148108 2013-03-15

Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma

Telik

Phase 2 Completed
14 enrolled
LymphoidPlasma cell

Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡